This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
monoclonal antibodies | 917 |
monoclonal antibody | 636 |
blood donors | 631 |
blood transfusion | 543 |
phage display | 489 |
immune response | 418 |
neutralizing antibodies | 405 |
blood components | 378 |
blood donation | 364 |
immune system | 360 |
whole blood | 344 |
antibody responses | 323 |
immune responses | 311 |
human monoclonal | 310 |
blood products | 291 |
respiratory syndrome | 282 |
red blood | 274 |
antibody response | 273 |
red cell | 271 |
specific antibodies | 260 |
infectious diseases | 259 |
neutralizing antibody | 251 |
clinical trials | 243 |
acute respiratory | 236 |
antibody titers | 232 |
transfusion medicine | 223 |
infected cells | 219 |
severe acute | 212 |
virus infection | 211 |
blood group | 209 |
intravenous immunoglobulin | 205 |
immunodeficiency virus | 204 |
red cells | 201 |
antibody fragments | 199 |
blood cells | 197 |
influenza virus | 190 |
human immunodeficiency | 188 |
specific antibody | 180 |
immune complexes | 175 |
neutralizing activity | 173 |
amino acid | 172 |
broadly neutralizing | 168 |
bone marrow | 164 |
platelet concentrates | 163 |
igg antibodies | 159 |
human igg | 156 |
convalescent plasma | 156 |
blood donor | 156 |
virus type | 151 |
escherichia coli | 147 |
blood units | 145 |
nucleic acid | 141 |
blood collection | 141 |
cell surface | 141 |
cord uid | 140 |
doc id | 140 |
blood banks | 139 |
blood samples | 138 |
binding site | 138 |
bispecific antibodies | 137 |
may also | 135 |
human antibody | 135 |
blood cell | 130 |
heavy chain | 129 |
egg yolk | 128 |
blood bank | 128 |
light chain | 127 |
side effects | 124 |
ng ml | 122 |
passive immunization | 121 |
effector functions | 120 |
viral infections | 120 |
gene therapy | 119 |
lupus erythematosus | 117 |
adverse events | 117 |
cell lines | 117 |
mg ml | 116 |
filamentous phage | 116 |
rheumatoid arthritis | 115 |
high affinity | 115 |
infectious disease | 113 |
igg antibody | 113 |
peripheral blood | 112 |
transfusion service | 111 |
antibody production | 111 |
animal models | 111 |
pregnant women | 111 |
western blot | 110 |
transfusion reactions | 110 |
passive immunity | 109 |
systemic lupus | 109 |
therapeutic antibodies | 108 |
serum samples | 106 |
platelet count | 106 |
human antibodies | 105 |
flow cytometry | 104 |
respiratory syncytial | 103 |
significantly higher | 103 |
sars coronavirus | 103 |
viral infection | 102 |
antibody binding | 102 |
bacterial contamination | 102 |
chain variable | 102 |
united states | 102 |
positive results | 101 |
bispecific antibody | 99 |
mg kg | 99 |
complement activation | 98 |
room temperature | 98 |
syncytial virus | 98 |
light chains | 97 |
antibody titer | 97 |
significant difference | 96 |
control group | 96 |
measles virus | 95 |
recent years | 95 |
plasmodium falciparum | 95 |
protein microarrays | 95 |
virus neutralization | 95 |
syndrome coronavirus | 94 |
blood supply | 93 |
fc receptor | 93 |
amino acids | 93 |
dendritic cells | 93 |
autoimmune diseases | 92 |
dengue virus | 92 |
blood donations | 91 |
iu ml | 90 |
autologous blood | 88 |
cell line | 87 |
cell responses | 87 |
quality control | 86 |
immune globulin | 86 |
blood safety | 85 |
display technology | 85 |
recombinant antibodies | 84 |
growth factor | 84 |
herpes simplex | 84 |
antibody therapy | 83 |
hbv dna | 83 |
class i | 82 |
transfusion services | 81 |
polyclonal antibodies | 80 |
serum antibody | 79 |
antibody screening | 79 |
antibody levels | 79 |
antibody libraries | 79 |
goat anti | 79 |
target cells | 79 |
fully human | 79 |
domain antibodies | 79 |
viral antigens | 78 |
vaccine development | 78 |
iga antibodies | 78 |
single chain | 77 |
cell culture | 77 |
tumor cells | 76 |
ebola virus | 76 |
spike protein | 76 |
cancer cells | 76 |
performed using | 76 |
maternal antibodies | 76 |
antiglobulin test | 75 |
neutralizing human | 75 |
hybridoma technology | 75 |
adaptive immune | 74 |
first time | 74 |
factor viii | 74 |
innate immune | 73 |
antibody tests | 73 |
two different | 73 |
var csa | 72 |
blood component | 72 |
simplex virus | 71 |
public health | 71 |
hcv rna | 71 |
clinical trial | 71 |
critically ill | 71 |
viral load | 71 |
type i | 71 |
stem cell | 71 |
gamma globulin | 71 |
pg ml | 70 |
cell activation | 70 |
display library | 70 |
immunosorbent assay | 70 |
transmissible gastroenteritis | 70 |
platelet transfusion | 70 |
respiratory tract | 70 |
phase i | 69 |
two groups | 68 |
fusion protein | 68 |
cell receptor | 68 |
blood groups | 68 |
plasmon resonance | 68 |
scfv antibodies | 67 |
lateral flow | 67 |
commercially available | 67 |
cardiac surgery | 67 |
antibodies may | 67 |
binding affinity | 67 |
donor selection | 67 |
high levels | 67 |
surface plasmon | 67 |
antibody complexes | 66 |
human serum | 66 |
fc receptors | 66 |
cfu ml | 66 |
west nile | 66 |
mouse model | 66 |
recombinant antibody | 66 |
breast cancer | 66 |
frozen plasma | 66 |
linked immunosorbent | 66 |
alternative pathway | 65 |
national blood | 65 |
viral replication | 65 |
fusion proteins | 64 |
neutralizing monoclonal | 64 |
previously described | 64 |
immune cells | 64 |
infected individuals | 64 |
antibody library | 63 |
binding domain | 63 |
receptor binding | 63 |
infected patients | 63 |
affinity maturation | 63 |
igm antibodies | 63 |
serum igg | 62 |
stem cells | 62 |
immunoglobulin therapy | 62 |
clinical use | 62 |
blood service | 62 |
fresh frozen | 61 |
single domain | 61 |
blood services | 61 |
igy antibodies | 60 |
statistically significant | 60 |
rabies virus | 60 |
negative control | 60 |
protective immunity | 60 |
antibodies directed | 60 |
necrosis factor | 60 |
surface antigen | 60 |
serum therapy | 59 |
antibody testing | 59 |
immune complex | 59 |
antibody fragment | 59 |
large number | 59 |
mumps virus | 58 |
passive transfer | 58 |
monoclonal anti | 58 |
epitope mapping | 58 |
nk cells | 58 |
passive immunotherapy | 58 |
display libraries | 58 |
electron microscopy | 58 |
cancer therapy | 58 |
viral proteins | 58 |
patients undergoing | 57 |
infectious agents | 57 |
novel coronavirus | 57 |
transfusion therapy | 57 |
plasma samples | 57 |
nile virus | 57 |
blood banking | 56 |
widely used | 56 |
blood loss | 56 |
envelope glycoprotein | 56 |
ill patients | 56 |
human immunoglobulin | 55 |
viral antigen | 55 |
test results | 55 |
vaccinia virus | 55 |
bacterial infections | 55 |
reactive antibodies | 55 |
specific igg | 55 |
important role | 54 |
case report | 54 |
scansystem tm | 54 |
three times | 54 |
based therapies | 54 |
hbv infection | 54 |
humoral immune | 54 |
high throughput | 53 |
highly conserved | 53 |
positive samples | 53 |
false positive | 53 |
chain reaction | 53 |
see table | 53 |
staphylococcus aureus | 53 |
pm dm | 53 |
clinical signs | 53 |
polyclonal antibody | 53 |
antigen binding | 52 |
polymerase chain | 52 |
specific monoclonal | 52 |
health care | 52 |
barr virus | 52 |
cord blood | 52 |
human mabs | 52 |
recombinant proteins | 52 |
patients receiving | 52 |
chain antibodies | 52 |
protein expression | 51 |
human anti | 51 |
transfusion practice | 51 |
plasma cells | 51 |
adverse reactions | 51 |
antigen receptor | 51 |
molecular weight | 51 |
transgenic mice | 51 |
last years | 51 |
platelets stored | 51 |
antibodies specific | 51 |
guinea pig | 50 |
donate blood | 50 |
host cell | 50 |
antibodies targeting | 50 |
host immune | 50 |
systematic review | 50 |
results show | 50 |
statistical analysis | 50 |
fab fragments | 50 |
present study | 50 |
therapeutic efficacy | 49 |
virus vaccine | 49 |
domain antibody | 49 |
mhc class | 49 |
buffy coat | 49 |
variable domain | 49 |
risk factors | 49 |
red cross | 49 |
natural killer | 49 |
dependent enhancement | 49 |
antibody test | 49 |
coronavirus disease | 49 |
clinical practice | 49 |
binding sites | 48 |
clinically significant | 48 |
porcine reproductive | 48 |
variable regions | 48 |
healthy donors | 48 |
heavy chains | 48 |
human immune | 48 |
coronavirus antibody | 48 |
even though | 48 |
secondary antibody | 48 |
birth weight | 47 |
positive control | 47 |
safe blood | 47 |
positive result | 47 |
host cells | 47 |
high risk | 47 |
cd cells | 47 |
recombinant human | 47 |
antibody repertoire | 47 |
days post | 47 |
direct antiglobulin | 47 |
potent neutralizing | 47 |
viral diseases | 47 |
single cell | 46 |
antigen detection | 46 |
variable fragment | 46 |
may occur | 46 |
chain antibody | 46 |
high sensitivity | 46 |
class ii | 46 |
igg fc | 46 |
tumor necrosis | 46 |
chicken egg | 46 |
blood centre | 46 |
university hospital | 46 |
connective tissue | 46 |
blood centers | 46 |
therapeutic antibody | 46 |
wide range | 45 |
blood pressure | 45 |
intensive care | 45 |
adverse effects | 45 |
immune serum | 45 |
mononuclear cells | 45 |
pathogen inactivation | 45 |
cell cultures | 45 |
chimeric antigen | 45 |
cd cd | 45 |
respiratory distress | 45 |
hiv infection | 45 |
fetal dna | 45 |
animal model | 45 |
binding activity | 45 |
passive protection | 45 |
positive antibody | 44 |
therapeutic mabs | 44 |
virus infections | 44 |
total number | 44 |
years old | 44 |
fc region | 44 |
yolk antibodies | 44 |
naturally occurring | 44 |
effector cells | 44 |
high frequency | 44 |
variable region | 44 |
pcr assay | 44 |
influenza vaccine | 44 |
high level | 44 |
blood product | 44 |
antibody phage | 44 |
informed consent | 44 |
previous studies | 44 |
antibody gene | 44 |
antibody titres | 44 |
significant differences | 44 |
recent studies | 44 |
target cell | 43 |
protein microarray | 43 |
plasma therapy | 43 |
potent neutralization | 43 |
botulinum neurotoxin | 43 |
results suggest | 43 |
using phage | 43 |
antibody generation | 43 |
clostridium difficile | 43 |
least one | 43 |
ex vivo | 43 |
syndrome virus | 42 |
animal species | 42 |
protective efficacy | 42 |
blood center | 42 |
general hospital | 42 |
sars patients | 42 |
viral vectors | 42 |
mumps vaccine | 42 |
commonly used | 42 |
nucleic acids | 42 |
virus isolation | 42 |
existing antibodies | 42 |
associated coronavirus | 42 |
affi nity | 42 |
gel test | 42 |
rbc transfusion | 42 |
lung injury | 42 |
cov infection | 42 |
serum antibodies | 42 |
antibodies produced | 42 |
surface antigens | 42 |
bfe changes | 41 |
recent study | 41 |
clinical studies | 41 |
time pcr | 41 |
sle patients | 41 |
voluntary blood | 41 |
results obtained | 41 |
antibody detection | 41 |
antibody identification | 41 |
storage time | 40 |
complement system | 40 |
cell response | 40 |
replacement therapy | 40 |
gene transfer | 40 |
specific igy | 40 |
enveloped viruses | 40 |
dependent cellular | 40 |
feline infectious | 40 |
therapeutic potential | 40 |
years ago | 40 |
buffy coats | 40 |
nervous system | 40 |
body weight | 40 |
infectious peritonitis | 40 |
live attenuated | 40 |
structural proteins | 40 |
blood volume | 40 |
several studies | 39 |
virus vaccines | 39 |
epithelial cells | 39 |
type ii | 39 |
viral entry | 39 |
hla antibodies | 39 |
increased risk | 39 |
platelet pools | 39 |
new york | 39 |
cell membrane | 39 |
cd binding | 39 |
anti hpa | 39 |
enzyme immunoassay | 39 |
virus particles | 39 |
chain fv | 38 |
mouth disease | 38 |
infectious virus | 38 |
negative results | 38 |
hcv infection | 38 |
results indicate | 38 |
per year | 38 |
drug administration | 38 |
per unit | 38 |
rare blood | 38 |
determine whether | 38 |
year old | 38 |
humoral immunity | 38 |
mer rpl | 38 |
factor receptor | 38 |
quality system | 38 |
world health | 38 |
quality assurance | 38 |
dose intravenous | 38 |
septic shock | 37 |
live virus | 37 |
high specificity | 37 |
synovial fluid | 37 |
natural infection | 37 |
encephalitis virus | 37 |
expression levels | 37 |
hb level | 37 |
phage library | 37 |
blot analysis | 37 |
rabbit igg | 37 |
clinical development | 37 |
donor screening | 37 |
low levels | 37 |
age group | 36 |
animal viruses | 36 |
controlled trial | 36 |
information security | 36 |
therapeutic agents | 36 |
mediated cytotoxicity | 36 |
tm platelet | 36 |
plt count | 36 |
quality management | 36 |
bacterial detection | 36 |
significantly lower | 36 |
positive dat | 36 |
hbc positive | 36 |
membrane protein | 36 |
hla class | 36 |
infectious agent | 36 |
surface proteins | 36 |
placental infection | 36 |
different types | 36 |
healthy individuals | 36 |
antibodies using | 36 |
platelet kit | 36 |
three different | 36 |
iga antibody | 36 |
mass spectrometry | 36 |
blood establishments | 36 |
may lead | 36 |
polyclonal anti | 36 |
large numbers | 36 |
crystal structure | 36 |
mucosal immunity | 36 |
antibodies isolated | 35 |
detection limit | 35 |
bovine serum | 35 |
cytokine storm | 35 |
allogeneic blood | 35 |
donated blood | 35 |
immunized animals | 35 |
solid phase | 35 |
general population | 35 |
spleen cells | 35 |
cancer immunotherapy | 35 |
cell therapy | 35 |
igm antibody | 35 |
cell count | 35 |
plasma fractionation | 35 |
patients treated | 35 |
viral rna | 35 |
i ii | 35 |
first step | 35 |
coagulation factors | 35 |
coronavirus infection | 35 |
viral particles | 35 |
data suggest | 35 |
mediated immunity | 35 |
antigen presentation | 35 |
vaccine candidates | 35 |
middle east | 35 |
therapeutic applications | 35 |
membrane proteins | 35 |
mortality rate | 35 |
mouse igg | 35 |
rheumatoid factor | 35 |
cell separator | 35 |
antibody titre | 35 |
high dose | 35 |
units per | 35 |
antibody molecules | 34 |
envelope protein | 34 |
mouse monoclonal | 34 |
fc fragment | 34 |
cells expressing | 34 |
cells infected | 34 |
coat protein | 34 |
primary immunodeficiency | 34 |
long term | 34 |
vero cells | 34 |
cancer patients | 34 |
salmonella typhimurium | 34 |
described previously | 34 |
sickle cell | 34 |
hong kong | 34 |
endothelial cells | 34 |
highly specific | 34 |
innate immunity | 34 |
solid tumors | 34 |
tumor cell | 34 |
intravenous immune | 34 |
molecular biology | 34 |
cellular cytotoxicity | 34 |
window period | 34 |
female donors | 34 |
rabbit anti | 34 |
scfv antibody | 34 |
indirect antiglobulin | 34 |
neutralizing mabs | 34 |
human il | 34 |
alloimmune thrombocytopenia | 34 |
small number | 34 |
circulating antibodies | 33 |
enzyme treated | 33 |
antibody expression | 33 |
neutralizing epitopes | 33 |
severe thrombocytopenia | 33 |
blood transfusions | 33 |
antibody concentration | 33 |
vaccine design | 33 |
transfusion safety | 33 |
post transfusion | 33 |
clinical symptoms | 33 |
fully automated | 33 |
reverse transcriptase | 33 |
igg molecules | 33 |
constant regions | 33 |
significantly reduced | 33 |
hemolytic anemia | 33 |
nasal secretions | 33 |
antibody therapeutics | 33 |
cell epitopes | 33 |
bacterial screening | 33 |
plasmid dna | 33 |
closely related | 33 |
donor blood | 32 |
binding protein | 32 |
clinical samples | 32 |
transfused patients | 32 |
equine influenza | 32 |
secretory iga | 32 |
specific igm | 32 |
control groups | 32 |
cd antibody | 32 |
conjugated goat | 32 |
mammalian cells | 32 |
mucosal immune | 32 |
mmr vaccine | 32 |
platelet storage | 32 |
guinea pigs | 32 |
taken together | 32 |
variable domains | 32 |
gene expression | 32 |
cryptococcus neoformans | 32 |
mean age | 32 |
health organization | 32 |
infected cell | 32 |
chikungunya virus | 32 |
pseudomonas aeruginosa | 32 |
disease virus | 32 |
time donors | 32 |
protect mice | 32 |
inflammatory diseases | 32 |
antibody therapies | 32 |
specific anti | 31 |
serum iga | 31 |
single donor | 31 |
abo blood | 31 |
therapeutic use | 31 |
different species | 31 |
myeloma cells | 31 |
target antigen | 31 |
antibody complex | 31 |
specific antigens | 31 |
lymphoid cells | 31 |
antibody discovery | 31 |
platelet quality | 31 |
column agglutination | 31 |
bacterial growth | 31 |
group system | 31 |
multiple sclerosis | 31 |
recombinant protein | 31 |
candida albicans | 31 |
streptococcus mutans | 31 |
complement fixation | 31 |
care unit | 31 |
structural basis | 31 |
cell fusion | 31 |
immune sera | 31 |
cell concentrates | 31 |
cell sorting | 31 |
also used | 31 |
antiviral drugs | 31 |
antibody sequences | 31 |
human sera | 31 |
filamentous bacteriophage | 31 |
biotinylated antibodies | 31 |
well tolerated | 31 |
results showed | 31 |
serological assays | 31 |
times higher | 31 |
vaccination strategies | 31 |
phage displaying | 31 |
pathogen detection | 31 |
affinity antibodies | 31 |
platelet antigens | 30 |
haemolytic disease | 30 |
gastroenteritis virus | 30 |
plasma products | 30 |
transfusion transmitted | 30 |
distress syndrome | 30 |
trauma patients | 30 |
somatic mutations | 30 |
negative controls | 30 |
time blood | 30 |
reagent lots | 30 |
platelet products | 30 |
antibody engineering | 30 |
least two | 30 |
phase iii | 30 |
vaccine efficacy | 30 |
host disease | 30 |
protein array | 30 |
one case | 30 |
acid residues | 30 |
yellow fever | 30 |
igg subclasses | 30 |
cell wall | 30 |
another study | 30 |
dental caries | 30 |
see chapter | 30 |
serious adverse | 30 |
additive solution | 30 |
th cells | 30 |
cell types | 30 |
disease control | 30 |
study showed | 30 |
within hours | 30 |
cov spike | 30 |
surface protein | 30 |
per patient | 30 |
transfusion reaction | 30 |
binding antibodies | 30 |
horseradish peroxidase | 30 |
may cause | 30 |
blood sample | 29 |
significantly increased | 29 |
hospital transfusion | 29 |
maternal antibody | 29 |
gold nanoparticles | 29 |
protein interactions | 29 |
neonatal alloimmune | 29 |
will allow | 29 |
fc fusion | 29 |
lactogenic immunity | 29 |
antibodies generated | 29 |
extremely rare | 29 |
antibiotic therapy | 29 |
also known | 29 |
antibody activity | 29 |
protective effect | 29 |
influenza viruses | 29 |
outer membrane | 29 |
central nervous | 29 |
cancer cell | 29 |
corrective actions | 29 |
viral inactivation | 29 |
also observed | 29 |
plasma transfusion | 29 |
treated rbcs | 29 |
mycobacterium tuberculosis | 29 |
acid sequence | 29 |
wild type | 29 |
canine parvovirus | 29 |
antibody specificity | 29 |
therapeutic monoclonal | 29 |
phase ii | 29 |
lung cancer | 29 |
like particles | 29 |
negative blood | 29 |
allergic reactions | 29 |
mean value | 29 |
presenting cells | 29 |
neonatal fc | 29 |
clinical applications | 28 |
nucleocapsid protein | 28 |
virus entry | 28 |
recent advances | 28 |
significant antibodies | 28 |
relatively high | 28 |
cell receptors | 28 |
high quality | 28 |
young people | 28 |
mediated immune | 28 |
rbc units | 28 |
target antigens | 28 |
genetically engineered | 28 |
positive donors | 28 |
effector function | 28 |
conventional antibodies | 28 |
premature infants | 28 |
molecules per | 28 |
ml kg | 28 |
donor base | 28 |
humoral response | 28 |
platelet transfusions | 28 |
cell lymphoma | 28 |
previously reported | 28 |
neutralising antibody | 28 |
effector cell | 28 |
adaptive immunity | 28 |
significant reduction | 28 |
marrow transplantation | 28 |
whole virus | 28 |
three patients | 28 |
lymph nodes | 28 |
specific cd | 28 |
innate lymphoid | 28 |
based vaccines | 28 |
cd bs | 28 |
specific human | 28 |
also shown | 28 |
drug delivery | 28 |
cells ml | 28 |
mouse models | 28 |
hemorrhagic fever | 28 |
escape mutants | 27 |
linear epitope | 27 |
related complications | 27 |
cross reactivity | 27 |
biotinylated antibody | 27 |
conformational changes | 27 |
expressing cells | 27 |
highly sensitive | 27 |
significant increase | 27 |
reported cases | 27 |
last two | 27 |
plasma derivates | 27 |
placental malaria | 27 |
hospitalized patients | 27 |
antibody specific | 27 |
cd monoclonal | 27 |
tissue culture | 27 |
disease activity | 27 |
relatively low | 27 |
drug conjugates | 27 |
serum albumin | 27 |
envelope glycoproteins | 27 |
cd cell | 27 |
post irradiation | 27 |
east respiratory | 27 |
veterinary medicine | 27 |
dextransucrase antibody | 27 |
chemokine receptor | 27 |
positive cells | 27 |
one patient | 27 |
effective treatment | 27 |
viral pathogens | 27 |
within days | 27 |
clinical efficacy | 27 |
bacillus anthracis | 27 |
well plates | 27 |
neutralization test | 27 |
cell transplantation | 27 |
randomized controlled | 27 |
serological testing | 27 |
human igm | 27 |
plasma membrane | 27 |
may provide | 27 |
human rotavirus | 27 |
currently available | 27 |
molecular methods | 27 |
protective antibodies | 27 |
human origin | 26 |
autoimmune disease | 26 |
gel electrophoresis | 26 |
bovine coronavirus | 26 |
immune libraries | 26 |
hpa antibodies | 26 |
routine use | 26 |
short period | 26 |
regression analysis | 26 |
rights reserved | 26 |
inactivated vaccine | 26 |
therapeutic effect | 26 |
vaccine failure | 26 |
generation sequencing | 26 |
oral administration | 26 |
passive antibody | 26 |
inflammatory cytokines | 26 |
classical pathway | 26 |
transplant recipients | 26 |
antiphospholipid syndrome | 26 |
small amounts | 26 |
alkaline phosphatase | 26 |
rhesus macaques | 26 |
disease severity | 26 |
sequence analysis | 26 |
expression system | 26 |
summary conclusions | 26 |
brain barrier | 26 |
assay format | 26 |
magnetic nanoparticles | 26 |
fever virus | 26 |
growth factors | 26 |
many countries | 26 |
highly potent | 26 |
nonneutralized fraction | 26 |
low level | 26 |
epidermal growth | 26 |
regional blood | 26 |
antibody directed | 26 |
shiga toxin | 26 |
will help | 25 |
gastrointestinal tract | 25 |
influenza vaccines | 25 |
may result | 25 |
transmitted infections | 25 |
phage libraries | 25 |
bovine colostrum | 25 |
two years | 25 |
study group | 25 |
endemic areas | 25 |
somatic hypermutation | 25 |
virus load | 25 |
czech republic | 25 |
fc gamma | 25 |
fab fragment | 25 |
zika virus | 25 |
acute lung | 25 |
past years | 25 |
neutralizing anti | 25 |
biofilm formation | 25 |
laboratory diagnosis | 25 |
western blotting | 25 |
staphylococcal enterotoxin | 25 |
using antibody | 25 |
mean platelet | 25 |
display system | 25 |
dna vaccine | 25 |
based therapeutics | 25 |
using different | 25 |
high titers | 25 |
two patients | 25 |
detection methods | 25 |
listeria monocytogenes | 25 |
specific binding | 25 |
cell free | 25 |
th day | 25 |
general practitioners | 25 |
nipah virus | 25 |
specific immune | 25 |
histocompatibility complex | 25 |
also found | 25 |
combinatorial antibody | 25 |
data indicate | 25 |
single dose | 25 |
severe covid | 25 |
immune library | 25 |
pancreatic cancer | 25 |
fibrin glue | 25 |
normal human | 24 |
different methods | 24 |
cytopathic effect | 24 |
limited number | 24 |
pall ebds | 24 |
new technology | 24 |
cellular immunity | 24 |
per rbc | 24 |
viral shedding | 24 |
mg dl | 24 |
year period | 24 |
five years | 24 |
serologic tests | 24 |
malaria vaccine | 24 |
medical center | 24 |
causative agent | 24 |
virus replication | 24 |
ultrio assay | 24 |
negative result | 24 |
surgery patients | 24 |
will also | 24 |
bound antibody | 24 |
active immunization | 24 |
ana lysis | 24 |
capsid protein | 24 |
antibody interactions | 24 |
cells secreting | 24 |
control samples | 24 |
many different | 24 |
authors declare | 24 |
national institute | 24 |
hiv antibodies | 24 |
ii clinical | 24 |
antibodies binding | 24 |
gene delivery | 24 |
large amounts | 24 |
dependent cell | 24 |
myasthenia gravis | 24 |
murine monoclonal | 24 |
protein arrays | 24 |
clinical outcome | 24 |
thalassemic patients | 24 |
antiphospholipid antibodies | 24 |
analysis showed | 24 |
mucosal surfaces | 24 |
years later | 24 |
cancer treatment | 24 |
high titer | 24 |
clinical settings | 24 |
rich plasma | 24 |
next generation | 24 |
based assays | 24 |
platelet concentration | 24 |
high concentrations | 24 |
group antigens | 24 |
major histocompatibility | 24 |
antibody may | 24 |
pcr amplification | 24 |
infected pigs | 24 |
plaque reduction | 24 |
viral vector | 24 |
serological tests | 24 |
adverse reaction | 24 |
van der | 24 |
mumps infection | 23 |
haemolytic anaemia | 23 |
biological activity | 23 |
immunoglobulin preparations | 23 |
transgenic plants | 23 |
human recombinant | 23 |
many cases | 23 |
human platelet | 23 |
primary antibody | 23 |
vaccine strain | 23 |
fab i | 23 |
neutralization assay | 23 |
hela cells | 23 |
antigenic determinants | 23 |
clinical course | 23 |
rapid detection | 23 |
time points | 23 |
serum half | 23 |
mabs may | 23 |
emerging infectious | 23 |
antibody targeting | 23 |
four different | 23 |
immunoglobulin replacement | 23 |
data set | 23 |
ml per | 23 |
two decades | 23 |
infected mice | 23 |
binding proteins | 23 |
viral antibody | 23 |
anticardiolipin antibodies | 23 |
coiled coil | 23 |
may require | 23 |
cell antigens | 23 |
inflammatory responses | 23 |
white cell | 23 |
expression vector | 23 |
positive sera | 23 |
uric acid | 23 |
prostate cancer | 23 |
surface display | 23 |
white blood | 23 |
mediated neutralization | 23 |
cells via | 23 |
take place | 23 |
may reduce | 23 |
helicobacter pylori | 23 |
virus envelope | 23 |
hematopoietic cells | 23 |
one single | 23 |
ml min | 23 |
determining regions | 23 |
following vaccination | 23 |
nonhuman primates | 23 |
detected using | 23 |
naturally infected | 23 |
fused cells | 23 |
vitro studies | 23 |
per well | 23 |
fmd virus | 23 |
low cost | 23 |
antibody screen | 22 |
blood system | 22 |
donor cells | 22 |
ethnic groups | 22 |
mumps outbreaks | 22 |
fab library | 22 |
mammalian cell | 22 |
medical staff | 22 |
borrelia burgdorferi | 22 |
avian influenza | 22 |
specific antigen | 22 |
may play | 22 |
sandwich elisa | 22 |
renal disease | 22 |
virus neutralizing | 22 |
hemolytic transfusion | 22 |
diagnostic tests | 22 |
culture supernatant | 22 |
retrospective analysis | 22 |
vivo expression | 22 |
unpublished data | 22 |
compatible platelets | 22 |
platelet concentrate | 22 |
neutralizing potency | 22 |
among patients | 22 |
oral immunization | 22 |
allogenic blood | 22 |
myocardial infarction | 22 |
neutralization assays | 22 |
like receptors | 22 |
combination therapy | 22 |
rabbit serum | 22 |
circumsporozoite protein | 22 |
two doses | 22 |
natural antibodies | 22 |
cell function | 22 |
final concentration | 22 |
virus shedding | 22 |
clinical disease | 22 |
definitive diagnosis | 22 |
cell lung | 22 |
transfusion chain | 22 |
cytokine release | 22 |
using monoclonal | 22 |
subunit vaccine | 22 |
igg concentrates | 22 |
conformational epitopes | 22 |
european countries | 22 |
convalescent serum | 22 |
transfusion center | 22 |
bacterial pathogens | 22 |
human mab | 22 |
constant region | 22 |
blood flow | 22 |
protective immune | 22 |
sorted cells | 22 |
will provide | 22 |
rotavirus infection | 22 |
plasma donors | 22 |
serum sample | 22 |
cellular immune | 22 |
virus challenge | 22 |
group i | 22 |
protective antigen | 22 |
well known | 22 |
bacterial infection | 22 |
low risk | 22 |
two major | 22 |
associated virus | 22 |
successfully used | 22 |
humanized mice | 22 |
effective vaccines | 22 |
specific mabs | 22 |
patients suffering | 22 |
cell death | 22 |
one day | 22 |
last decade | 22 |
vascular endothelial | 22 |
humanized antibody | 22 |
immunoglobulin genes | 22 |
clinical stage | 22 |
also tested | 22 |
one study | 22 |
seroconversion panels | 22 |
corticosteroid treatment | 22 |
blood lymphocytes | 21 |
gene products | 21 |
deferred donors | 21 |
blood plasma | 21 |
antiviral immune | 21 |
agglutination technology | 21 |
many years | 21 |
blood collected | 21 |
excessive bleeding | 21 |
data analysis | 21 |
probably due | 21 |
bact alert | 21 |
high antibody | 21 |
low birthweight | 21 |
two methods | 21 |
protective antibody | 21 |
rhesus monkeys | 21 |
toxoplasma gondii | 21 |
large scale | 21 |
predonation hb | 21 |
rhd gamma | 21 |
lymphoid tissues | 21 |
old individuals | 21 |
laboratory testing | 21 |
immune effector | 21 |
transfusion related | 21 |
pandemic influenza | 21 |
severe cases | 21 |
donor population | 21 |
humanized monoclonal | 21 |
convalescent patients | 21 |
one year | 21 |
magnetic cards | 21 |
simultaneous detection | 21 |
patients received | 21 |
cell proliferation | 21 |
real time | 21 |
cde cde | 21 |
synergistic neutralization | 21 |
toxic shock | 21 |
vista tm | 21 |
antigenic modulation | 21 |
measured using | 21 |
open reading | 21 |
coronavirus spike | 21 |
mean hb | 21 |
mediated effector | 21 |
effective use | 21 |
samples collected | 21 |
reverse transcription | 21 |
mg day | 21 |
different animal | 21 |
hcv antibodies | 21 |
bacterial strains | 21 |
primary immunodeficiencies | 21 |
active immunity | 21 |
inhibitory activity | 21 |
humanized antibodies | 21 |
affinity chromatography | 21 |
killer cells | 21 |
subunit vaccines | 21 |
yeast surface | 21 |
transfusion policy | 21 |
time consuming | 21 |
patient received | 21 |
polyethylene glycol | 21 |
sequence identity | 21 |
antiviral antibody | 21 |
blood mononuclear | 21 |
tyrosine kinase | 21 |
cell transfusion | 21 |
human plasma | 21 |
surface expression | 21 |
severe disease | 21 |
primed donor | 21 |
protects mice | 21 |
gold standard | 21 |
platelet refractoriness | 21 |
specifi city | 21 |
igg mab | 21 |
repertoire mining | 21 |
murine model | 21 |
liver disease | 21 |
early detection | 21 |
clinical setting | 21 |
domain iii | 21 |
organ transplantation | 20 |
gnotobiotic pigs | 20 |
therapeutic mab | 20 |
antibody protects | 20 |
blood grouping | 20 |
also demonstrated | 20 |
antigenic specificity | 20 |
reduced mortality | 20 |
less frequent | 20 |
tetanus toxin | 20 |
helical coiled | 20 |
using two | 20 |
false negative | 20 |
specific ige | 20 |
tissue damage | 20 |
marrow transplant | 20 |
clinically relevant | 20 |
von behring | 20 |
national health | 20 |
bacterial cells | 20 |
spytag spycatcher | 20 |
mumps outbreak | 20 |
clinical benefit | 20 |
two weeks | 20 |
nodavirus antibody | 20 |
anthrax toxin | 20 |
shock syndrome | 20 |
may contribute | 20 |
controlled clinical | 20 |
fda approved | 20 |
thromboembolic events | 20 |
experimentally infected | 20 |
bovine rotavirus | 20 |
donor recruitment | 20 |
national haemovigilance | 20 |
amperometric immunosensor | 20 |
blood screening | 20 |
reference laboratory | 20 |
expression vectors | 20 |
inflammatory response | 20 |
predictive value | 20 |
immunosensor based | 20 |
peptide libraries | 20 |
preliminary results | 20 |
different antibody | 20 |
neutralizing hiv | 20 |
sensitive detection | 20 |
three weeks | 20 |
broad spectrum | 20 |
cells using | 20 |
ge healthcare | 20 |
weeks gestation | 20 |
analysis using | 20 |
inactivated virus | 20 |
human coronaviruses | 20 |
safety profile | 20 |
emerging viruses | 20 |
retrospective study | 20 |
buffered saline | 20 |
well established | 20 |
plasma units | 20 |
using human | 20 |
dependent manner | 20 |
adult patients | 20 |
myeloma cell | 20 |
risk factor | 20 |
three years | 20 |
positive blood | 20 |
hepatitis virus | 20 |
leukocyte antibodies | 20 |
hiv positive | 20 |
washed three | 20 |
iron stores | 20 |
disease progression | 20 |
virus strains | 20 |
chicken igy | 20 |
control study | 20 |
working group | 20 |
low frequency | 20 |
tge virus | 20 |
delivery systems | 20 |
potential therapeutic | 20 |
tumor antigens | 20 |
antibody administration | 20 |
mice infected | 20 |
genital secretions | 20 |
based therapy | 20 |
also reported | 19 |
may help | 19 |
camelid single | 19 |
cells may | 19 |
well documented | 19 |
linear epitopes | 19 |
among different | 19 |
sample volume | 19 |
critical role | 19 |
thrombocytopenic purpura | 19 |
library construction | 19 |
throughput screening | 19 |
ten years | 19 |
positive reactions | 19 |
new zealand | 19 |
severe sepsis | 19 |
human neutralizing | 19 |
antibody formats | 19 |
receptor expression | 19 |
may explain | 19 |
repeat blood | 19 |
cd expression | 19 |
immunological memory | 19 |
highly efficient | 19 |
antibody repertoires | 19 |
decoy epitope | 19 |
single nucleotide | 19 |
human fc | 19 |
phage antibody | 19 |
hna antibodies | 19 |
first week | 19 |
vaccine immunogens | 19 |
thrombocytopenic patients | 19 |
bispecific single | 19 |
type virus | 19 |
risk reduction | 19 |
patients without | 19 |
coli cells | 19 |
randomly selected | 19 |
virus antibody | 19 |
six months | 19 |
clinical specimens | 19 |
acid testing | 19 |
different epitopes | 19 |
igg levels | 19 |
young adults | 19 |
porcine circovirus | 19 |
toxin neutralization | 19 |
mouse antibodies | 19 |
transfusion purpura | 19 |
intravenous immunoglobulins | 19 |
will likely | 19 |
hiv envelope | 19 |
cell lysates | 19 |
antibody preparations | 19 |
high avidity | 19 |
rbc transfusions | 19 |
high resolution | 19 |
life cycle | 19 |
hospital blood | 19 |
antibody fab | 19 |
volunteer donors | 19 |
preoperative autologous | 19 |
acute infection | 19 |
sg hev | 19 |
antiviral mabs | 19 |
multiplex pcr | 19 |
host response | 19 |
diabetes mellitus | 19 |
current status | 19 |
human disease | 19 |
immune repertoire | 19 |
apheresis platelet | 19 |
cell units | 19 |
studies using | 19 |
pig serum | 19 |
serological methods | 19 |
acid sequences | 19 |
gamma irradiation | 19 |
component therapy | 19 |
antibody genes | 19 |
animal studies | 19 |
direct detection | 19 |
active disease | 19 |
early stages | 19 |
surgical procedures | 19 |
three days | 19 |
treatment options | 19 |
antibodies induced | 19 |
major challenge | 19 |
low affinity | 18 |
fc fragments | 18 |
neutralising antibodies | 18 |
caucasian population | 18 |
blood establishment | 18 |
higher antibody | 18 |
bacterial viruses | 18 |
iron depletion | 18 |
antibodies anti | 18 |
united kingdom | 18 |
packed red | 18 |
inflammatory bowel | 18 |
clinical relevance | 18 |
positive controls | 18 |
first generation | 18 |
platelet counts | 18 |
massive transfusion | 18 |
dna binding | 18 |
patient serum | 18 |
high prevalence | 18 |
continuous cultures | 18 |
transmissible infections | 18 |
ns ns | 18 |
selectin expression | 18 |
neutralizing epitope | 18 |
inhibitory effect | 18 |
clinical situations | 18 |
rna viruses | 18 |
plaque assay | 18 |
transfusion trigger | 18 |
lst system | 18 |
magnetic beads | 18 |
equal volume | 18 |
standard methods | 18 |
low birth | 18 |
specific iga | 18 |
split inteins | 18 |
apheresis procedures | 18 |
transfusion hepatitis | 18 |
hybrid rhesus | 18 |
table shows | 18 |
better understanding | 18 |
promising results | 18 |
host defense | 18 |
cdr regions | 18 |
automated system | 18 |
cell panel | 18 |
two mabs | 18 |
homologous blood | 18 |
monolisa hcv | 18 |
human fab | 18 |
antibodies showed | 18 |
sle sera | 18 |
th centile | 18 |
envelope proteins | 18 |
donating blood | 18 |
procleix ultrio | 18 |
japanese encephalitis | 18 |
standard operating | 18 |
shear stress | 18 |
efficient method | 18 |
virus strain | 18 |
rbc collection | 18 |
newborn calves | 18 |
donor platelets | 18 |
potassium level | 18 |
cmv infection | 18 |
true positive | 18 |
partial ds | 18 |
gambro bct | 18 |
russian federation | 18 |
like receptor | 18 |
nitrocellulose membrane | 18 |
variable fragments | 18 |
yersinia pestis | 18 |
per day | 18 |
process time | 18 |
nk cell | 18 |
deficient mice | 18 |
end point | 18 |
inh titre | 18 |
optimised scansystem | 18 |
may reflect | 18 |
clinical status | 18 |
chondroitin sulfate | 18 |
low hb | 18 |
viral genome | 18 |
operating procedures | 18 |
converting enzyme | 18 |
vaccinated animals | 18 |
fc domain | 18 |
operative infections | 18 |
serum dilution | 18 |
iga response | 18 |
animals treated | 18 |
modified live | 18 |
synthetic human | 18 |
outcome review | 18 |
developed countries | 18 |
ocular secretions | 18 |
analyzed using | 18 |
neutralization potency | 18 |
patients infected | 18 |
piezoelectric immunosensor | 18 |
autovue innova | 18 |
antibody concentrations | 18 |
platelet yield | 18 |
virus glycoprotein | 18 |
viral glycoproteins | 18 |
cell separators | 18 |
endothelial growth | 18 |
influenza pandemic | 18 |
high incidence | 18 |
detection assays | 18 |
genomic dna | 18 |
total rna | 18 |
near future | 18 |
neutralizing effect | 18 |
epitope binning | 18 |
clinical diagnosis | 18 |
dependent antibody | 18 |
wt wt | 18 |
normal rhd | 18 |
haemophilus influenzae | 18 |
pulmonary edema | 18 |
human cd | 18 |
erythrocyte antibodies | 18 |
inhalational anthrax | 18 |
yeast display | 18 |
free fetal | 18 |
two types | 18 |
viral envelope | 18 |
transfusion centers | 18 |
derived antibodies | 18 |
study period | 18 |
used successfully | 18 |
control sera | 18 |
clinical manifestations | 18 |
different antibodies | 18 |
storage period | 18 |
coronavirus infections | 18 |
virus transmission | 18 |
influenza infection | 18 |
vox sang | 17 |
medicinal products | 17 |
infected donors | 17 |
vh gene | 17 |
clinical impact | 17 |
volunteer blood | 17 |
primary infection | 17 |
domestic animals | 17 |
broad range | 17 |
signal intensity | 17 |
early diagnosis | 17 |
human single | 17 |
difficile infection | 17 |
activating fcgrs | 17 |
scfv library | 17 |
immunocompromised patients | 17 |
highly effective | 17 |
differ significantly | 17 |
antibodies derived | 17 |
hybridoma cells | 17 |
information system | 17 |
tested negative | 17 |
antibody molecule | 17 |
lyme disease | 17 |
developing countries | 17 |
much lower | 17 |
first two | 17 |
transcription factor | 17 |
viral neutralization | 17 |
respiratory disease | 17 |
molecular mechanisms | 17 |
results may | 17 |
clinical evidence | 17 |
genetic material | 17 |
human cells | 17 |
short time | 17 |
molecular mimicry | 17 |
conformational epitope | 17 |
specific primers | 17 |
humanized anti | 17 |
two distinct | 17 |
wnv infection | 17 |
rabbit antibody | 17 |
young children | 17 |
rapid identification | 17 |
replacement donors | 17 |
lacteal secretions | 17 |
specific epitopes | 17 |
cell entry | 17 |
normal mice | 17 |
among others | 17 |
rotavirus antibodies | 17 |
study design | 17 |
elisa assays | 17 |
organ failure | 17 |
zoster virus | 17 |
antiphospholipid antibody | 17 |
controlled trials | 17 |
powerful tool | 17 |
linked immunoassay | 17 |
different anti | 17 |
klebsiella pneumoniae | 17 |
immune memory | 17 |
lower respiratory | 17 |
fi lm | 17 |
studies showed | 17 |
studies suggest | 17 |
potential donors | 17 |
potent hiv | 17 |
normal range | 17 |
affinity human | 17 |
alexa fluor | 17 |
antibody affinity | 17 |
higher prevalence | 17 |
viral disease | 17 |
gene sequences | 17 |
additional file | 17 |
igg monoclonal | 17 |
variable heavy | 17 |
secreting antibody | 17 |
adhesion molecule | 17 |
microtiter plate | 17 |
potential applications | 17 |
idiotypic antibodies | 17 |
ab titers | 17 |
neutralized virus | 17 |
will need | 17 |
chain fragment | 17 |
mediated phagocytosis | 17 |
process control | 17 |
antibody heavy | 17 |
hiv antibody | 17 |
tested positive | 17 |
genetic engineering | 17 |
positive test | 17 |
binding capacity | 17 |
cd i | 17 |
day post | 17 |
subsequent studies | 17 |
single injection | 17 |
humanized mabs | 17 |
ige immune | 17 |
potent cross | 17 |
tissue disease | 17 |
upper respiratory | 17 |
fc portion | 17 |
virus antibodies | 17 |
dependent cytotoxicity | 17 |
affinity binding | 17 |
also positive | 17 |
first transfusion | 17 |
murine mabs | 17 |
optical density | 17 |
random donor | 17 |
early stage | 17 |
viral etiology | 17 |
prp sc | 17 |
small molecule | 17 |
functional antibodies | 17 |
new blood | 17 |
platelet components | 17 |
chronic lymphocytic | 17 |
mammary gland | 17 |
healthy volunteers | 17 |
infected animals | 17 |
attenuated influenza | 17 |
management system | 17 |
antigenic sites | 17 |
prion protein | 17 |
cerebrospinal fluid | 17 |
pathogen reduction | 17 |
chicken antibodies | 16 |
predefined specificity | 16 |
reading frame | 16 |
male donors | 16 |
immune antibodies | 16 |
gel filtration | 16 |
hemolytic disease | 16 |
intravenous use | 16 |
median age | 16 |
european union | 16 |
stranded rna | 16 |
animals receiving | 16 |
inhibitory receptor | 16 |
dendritic cell | 16 |
highly vaccinated | 16 |
leukemia virus | 16 |
igg anti | 16 |
several years | 16 |
autoimmune hemolytic | 16 |
incubation period | 16 |
vn antibody | 16 |
transfusion activities | 16 |
antibody fc | 16 |
human use | 16 |
engineered antibody | 16 |
hbc negative | 16 |
make human | 16 |
antigen specific | 16 |
haemovigilance data | 16 |
high cost | 16 |
sample preparation | 16 |
antitumor activity | 16 |
will require | 16 |
circulatory overload | 16 |
components issued | 16 |
existing immunity | 16 |
per se | 16 |
antibody deficiency | 16 |
cell immunity | 16 |
vaccine candidate | 16 |
viral clearance | 16 |
findings suggest | 16 |
hiv gp | 16 |
per ml | 16 |
will continue | 16 |
also performed | 16 |
significant changes | 16 |
following transfusion | 16 |
spatial neighbors | 16 |
antibody recognition | 16 |
abo group | 16 |
rapid development | 16 |
antibody arrays | 16 |
core antigen | 16 |
challenge model | 16 |
local population | 16 |
viral hepatitis | 16 |
proinflammatory cytokines | 16 |
agglutination test | 16 |
clinical response | 16 |
pregnant woman | 16 |
negative bfe | 16 |
maternally derived | 16 |
working party | 16 |
fl uorescence | 16 |
related acute | 16 |
three blood | 16 |
rna detection | 16 |
immune cell | 16 |
old male | 16 |
antibody microarrays | 16 |
intercept blood | 16 |
kawasaki disease | 16 |
human blood | 16 |
also showed | 16 |
signal transduction | 16 |
antibody syndrome | 16 |
scarlet fever | 16 |
rna testing | 16 |
also included | 16 |
cd positive | 16 |
symptom onset | 16 |
antigen may | 16 |
muscle cells | 16 |
collaborative study | 16 |
genetically modified | 16 |
sample collection | 16 |
internal controls | 16 |
different antigens | 16 |
positive donations | 16 |
gestational age | 16 |
whole cell | 16 |
also present | 16 |
serial dilutions | 16 |
primary isolates | 16 |
well plate | 16 |
increased susceptibility | 16 |
three months | 16 |
inhibition assay | 16 |
viral nucleic | 16 |
samples obtained | 16 |
new technologies | 16 |
medical treatment | 16 |
antibodies raised | 16 |
high doses | 16 |
borne encephalitis | 16 |
killer cell | 16 |
one unit | 16 |
evaluated using | 16 |
adverse event | 16 |
synthetic peptides | 16 |
generate antibodies | 16 |
hendra virus | 16 |
febrile non | 16 |
viral capsid | 16 |
measurement system | 16 |
many patients | 16 |
quality assessment | 16 |
antibody variable | 16 |
small molecules | 16 |
rbc antigens | 16 |
clostridium botulinum | 16 |
random coils | 16 |
targeted delivery | 16 |
national guidelines | 16 |
clinically ill | 16 |
cohort studies | 16 |
mammary secretions | 16 |
protective effects | 16 |
prospective study | 16 |
weeks later | 16 |
standard serological | 16 |
colorectal cancer | 16 |
fluorescence microscopy | 16 |
global health | 16 |
assay results | 16 |
disulfide bonds | 16 |
medical doctors | 16 |
less effective | 16 |
positive patients | 16 |
manufacturing process | 16 |
higher doses | 16 |
one hour | 16 |
different routes | 16 |
primer pairs | 16 |
vaccinated individuals | 16 |
igg concentrate | 16 |
also examined | 16 |
fresh platelets | 15 |
electrical impedance | 15 |
contamination risk | 15 |
million inhabitants | 15 |
results demonstrate | 15 |
gpib expression | 15 |
bacterial culture | 15 |
months later | 15 |
adenovirus type | 15 |
detect antibodies | 15 |
ub ml | 15 |
human leukocyte | 15 |
haemovigilance systems | 15 |
external quality | 15 |
vast majority | 15 |
voluntary donors | 15 |
useful tool | 15 |
antibodies reactive | 15 |
autologous haemotherapy | 15 |
umbilical cord | 15 |
immune tolerance | 15 |
antibodies present | 15 |
cell antibodies | 15 |
comparing ffp | 15 |
described elsewhere | 15 |
fluorescent cells | 15 |
membrane fusion | 15 |
intrauterine transfusions | 15 |
donor deferrals | 15 |
may affect | 15 |
yolk immunoglobulin | 15 |
hcv antibody | 15 |
much higher | 15 |
maternal plasma | 15 |
protein synthesis | 15 |
igg level | 15 |
serologic testing | 15 |
quantum dot | 15 |
done using | 15 |
system antibodies | 15 |
igg molecule | 15 |
must also | 15 |
plasma factors | 15 |
highly immunogenic | 15 |
treated patients | 15 |
induced antibodies | 15 |
atomic force | 15 |
four hours | 15 |
like antibodies | 15 |
relative birth | 15 |
denv infection | 15 |
blood bags | 15 |
local blood | 15 |
plt transfusions | 15 |
drug resistance | 15 |
will lead | 15 |
free haemoglobin | 15 |
uremic syndrome | 15 |
circulating immune | 15 |
methods used | 15 |
antibody isotype | 15 |
functional antibody | 15 |
considered positive | 15 |
hours later | 15 |
conjugated anti | 15 |
epithelial cell | 15 |
positive rate | 15 |
immunogenic proteins | 15 |
control bags | 15 |
positive particles | 15 |
regular donors | 15 |
hour cci | 15 |
multiple myeloma | 15 |
clinical significance | 15 |
trali cases | 15 |
binding affinities | 15 |
hcv ag | 15 |
years period | 15 |
random donors | 15 |
serum ferritin | 15 |
adoptive immunotherapy | 15 |
cobe spectra | 15 |
may induce | 15 |
two human | 15 |
rhd immunization | 15 |
virulent rv | 15 |
cell apheresis | 15 |
alternative approach | 15 |
aiha patients | 15 |
secondary structure | 15 |
final product | 15 |
cd mab | 15 |
immune checkpoint | 15 |
heparin pf | 15 |
binding domains | 15 |
mica surface | 15 |
hinge region | 15 |
ip vs | 15 |
laboratory mistake | 15 |
plasma low | 15 |
routinely used | 15 |
human peripheral | 15 |
mbl levels | 15 |
hemagglutination inhibition | 15 |
international standard | 15 |
erythrocyte concentrates | 15 |
ovarian cancer | 15 |
spike antibody | 15 |
neutralizing effects | 15 |
detection system | 15 |
proteins may | 15 |
days later | 15 |
viral titers | 15 |
gene segments | 15 |
pregnancy outcomes | 15 |
immunized mice | 15 |
newly emerging | 15 |
rhd exons | 15 |
case group | 15 |
general hospitals | 15 |
mcmv viral | 15 |
standard deviation | 15 |
rhd positive | 15 |
th week | 15 |
chronic fatigue | 15 |
inhibitory fccriib | 15 |
platelet function | 15 |
spike glycoprotein | 15 |
phage coat | 15 |
low titer | 15 |
mmr vaccination | 15 |
like virus | 15 |
ebov gp | 15 |
hit patients | 15 |
cardiac diseases | 15 |
also important | 15 |
neutralizing mab | 15 |
emerging infections | 15 |
sexual partners | 15 |
infection may | 15 |
cell yield | 15 |
hematopoietic stem | 15 |
new donors | 15 |
fc effector | 15 |
cold antibodies | 15 |
derived platelets | 15 |
clinical conditions | 15 |
soluble protein | 15 |
drug discovery | 15 |
living space | 15 |
apoplastic fluid | 15 |
study included | 15 |
health sciences | 15 |
antibodies bound | 15 |
salmonella enterica | 15 |
blood derived | 15 |
plasma volume | 15 |
milk samples | 15 |
low molecular | 15 |
based assay | 15 |
external controls | 15 |
transient expression | 15 |
early responders | 15 |
dna typing | 15 |
culture supernatants | 15 |
antibody assays | 15 |
rh system | 15 |
receive blood | 15 |
analytical sensitivity | 15 |
treated platelets | 15 |
antigen receptors | 15 |
rare red | 15 |
th response | 15 |
human cytomegalovirus | 15 |
serially diluted | 15 |
cell adhesion | 15 |
term newborns | 15 |
group systems | 15 |
platelet rich | 15 |
rheumatic diseases | 15 |
treated animals | 15 |
human ig | 15 |
quality controls | 15 |
differences among | 15 |
phage particle | 15 |
also provide | 15 |
type gp | 15 |
rhd gene | 15 |
prestorage leucodepletion | 15 |
randomized trial | 15 |
hbsag prevalence | 15 |
platelet specific | 15 |
steric hindrance | 15 |
five patients | 15 |
au nps | 15 |
ii molecules | 15 |
culture medium | 15 |
hbsag negative | 15 |
health problem | 15 |
biologically active | 15 |
type envelope | 15 |
first report | 15 |
viral safety | 15 |
induced thrombocytopenia | 15 |
flow rate | 15 |
studies demonstrated | 15 |
mds patients | 15 |
alert system | 15 |
auto vue | 15 |
severe clinical | 15 |
framework regions | 15 |
transfusion institute | 15 |
virus particle | 15 |
cell disease | 15 |
apheresis procedure | 15 |
intestinal iga | 15 |
synthetic dna | 15 |
blood conservation | 15 |
campylobacter jejuni | 15 |
antigen antibody | 15 |
simian immunodeficiency | 15 |
successfully applied | 15 |
pbs containing | 15 |
pf antibody | 15 |
chronic hepatitis | 15 |
fresenius hemocare | 15 |
rbc abs | 15 |
humanized mab | 15 |
hemocue plasma | 15 |
fully synthetic | 15 |
relatively small | 15 |
maternal alloantibody | 15 |
restrictive transfusion | 15 |
results indicated | 15 |
showed high | 15 |
found positive | 15 |
normal controls | 15 |
whooping cough | 14 |
different concentrations | 14 |
donors will | 14 |
inflammatory reactions | 14 |
factor ix | 14 |
may vary | 14 |
mediated protection | 14 |
quartz crystal | 14 |
current study | 14 |
constructed using | 14 |
signaling pathways | 14 |
engineered antibodies | 14 |
iron deficiency | 14 |
immune status | 14 |
fatigue syndrome | 14 |
botulinum toxin | 14 |
therapeutic approaches | 14 |
fluorescent antibody | 14 |
statistical modelling | 14 |
activating fc | 14 |
response rate | 14 |
antibody technology | 14 |
large quantities | 14 |
antigen complexes | 14 |
using elisa | 14 |
deuterium exchange | 14 |
wide variety | 14 |
clinical evaluation | 14 |
conserved epitopes | 14 |
one woman | 14 |
human health | 14 |
screening test | 14 |
subacute sclerosing | 14 |
ig preparations | 14 |
chronic viral | 14 |
sciences authority | 14 |
cdrh identity | 14 |
synergistic neutralizing | 14 |
quantum dots | 14 |
transfusion associated | 14 |
chronic inflammatory | 14 |
denv diii | 14 |
higher concentration | 14 |
therapeutic effects | 14 |
body fluids | 14 |
antigen units | 14 |
i clinical | 14 |
several weeks | 14 |
cell killing | 14 |
active sle | 14 |
five days | 14 |
also obtained | 14 |
igg titers | 14 |
therapeutic strategies | 14 |
immune plasma | 14 |
transfusion committee | 14 |
partial protection | 14 |
mediated lysis | 14 |
aggregated igg | 14 |
received blood | 14 |
cell repertoire | 14 |
human population | 14 |
primary human | 14 |
binding properties | 14 |
generated using | 14 |
regular blood | 14 |
peer review | 14 |
positive individuals | 14 |
synthetic libraries | 14 |
falciparum malaria | 14 |
serologic assays | 14 |
high titre | 14 |
humoral responses | 14 |
surface area | 14 |
liver transplantation | 14 |
transfusion strategy | 14 |
immunoglobulin classes | 14 |
pilot study | 14 |
malaria infection | 14 |
occurring antibodies | 14 |
specific memory | 14 |
cell counts | 14 |
laboratory personnel | 14 |
binding specificity | 14 |
four years | 14 |
pathological conditions | 14 |
using recombinant | 14 |
method using | 14 |
cell development | 14 |
iga deficiency | 14 |
confer protection | 14 |
serious complications | 14 |
group antibodies | 14 |
cohort study | 14 |
specific serum | 14 |
major cause | 14 |
positive direct | 14 |
future studies | 14 |
particularly useful | 14 |
secretory component | 14 |
virus attachment | 14 |
i trial | 14 |
autoimmune haemolytic | 14 |
antibody prophylaxis | 14 |
local immunity | 14 |
disease onset | 14 |
passively acquired | 14 |
purified using | 14 |
patients showed | 14 |
attenuated virus | 14 |
reactive neutralizing | 14 |
mab approved | 14 |
new approach | 14 |
falciparum antigens | 14 |
elisa test | 14 |
mice immunized | 14 |
articular cartilage | 14 |
clinical illness | 14 |
compatibility testing | 14 |
secreting cells | 14 |
two samples | 14 |
negative patients | 14 |
young animals | 14 |
antiviral antibodies | 14 |
system may | 14 |
response may | 14 |
flow cytometer | 14 |
infected dogs | 14 |
graft versus | 14 |
disease transmission | 14 |
group antigen | 14 |
previously infected | 14 |
nzb mice | 14 |
falciparum infection | 14 |
active infection | 14 |
functional activity | 14 |
coat proteins | 14 |
split intein | 14 |
stimulating factor | 14 |
several advantages | 14 |
inhibitory receptors | 14 |
vivo antibody | 14 |
positive clones | 14 |
million people | 14 |
serum levels | 14 |
immune phage | 14 |
aqueous humor | 14 |
diagnostic purposes | 14 |
another important | 14 |
sialic acid | 14 |
following administration | 14 |
viral protein | 14 |
similar results | 14 |
iga class | 14 |
increasingly important | 14 |
sandwich assay | 14 |
bowel disease | 14 |
plasma pools | 14 |
protein binding | 14 |
physical examination | 14 |
kg body | 14 |
transfusion process | 14 |
extremely high | 14 |
antibodies recognizing | 14 |
antigen panning | 14 |
bartonella spp | 14 |
intravenous administration | 14 |
acid residue | 14 |
positive reaction | 14 |
renal failure | 14 |
second step | 14 |
calf serum | 14 |
normal subjects | 14 |
cells will | 14 |
like particle | 14 |
cytopathic effects | 14 |
highest dilution | 14 |
overlapping epitopes | 14 |
nobel prize | 14 |
tested using | 14 |
early phase | 14 |
nucleotide sequences | 14 |
antibody classes | 14 |
neisseria meningitidis | 14 |
merozoite surface | 14 |
life threatening | 14 |
basic research | 14 |
hemolytic uremic | 14 |
library constructed | 14 |
immune deficiency | 14 |
screening method | 14 |
asian population | 14 |
negative bacteria | 14 |
haemovigilance programme | 14 |
cell salvage | 14 |
fv antibody | 14 |
based methods | 14 |
increasing number | 14 |
antibody candidates | 14 |
internal medicine | 14 |
anaphylactic shock | 14 |
secondary antibodies | 14 |
cells per | 14 |
hbsag positive | 14 |
purified antibodies | 14 |
standard deviations | 14 |
acute lymphoblastic | 14 |
binding activities | 14 |
passively transferred | 14 |
increased significantly | 14 |
common variable | 14 |
selected antibodies | 14 |
bispecific igg | 14 |
fungal infections | 14 |
mrna encoding | 14 |
forming units | 14 |
nucleotide polymorphisms | 13 |
fold higher | 13 |
immune human | 13 |
phosphate buffer | 13 |
antibodies also | 13 |
human memory | 13 |
lymphoid tissue | 13 |
paratope identity | 13 |
facs screening | 13 |
stx holotoxin | 13 |
cell cytotoxicity | 13 |
negative samples | 13 |
rhd zygosity | 13 |
intravenous injection | 13 |
neonatal lupus | 13 |
health authorities | 13 |
acid amplification | 13 |
insertional mutagenesis | 13 |
helper cells | 13 |
patient safety | 13 |
broad neutralizing | 13 |
neutrophil activation | 13 |
donor platelet | 13 |
neutralize sars | 13 |
antibodies towards | 13 |
based detection | 13 |
cytomegalovirus infection | 13 |
igy technology | 13 |
paratope prediction | 13 |
fusion partner | 13 |
neonatal mice | 13 |
frequency antigens | 13 |
virus surface | 13 |
soluble form | 13 |
fecal samples | 13 |
new insights | 13 |
total igg | 13 |
detect low | 13 |
light microscopy | 13 |
antigenic variation | 13 |
widespread use | 13 |
diagnostic tool | 13 |
vital signs | 13 |
infected targets | 13 |
two categories | 13 |
higher frequency | 13 |
molecular basis | 13 |
patient population | 13 |
fi eld | 13 |
made available | 13 |
results demonstrated | 13 |
prophylactic anti | 13 |
chicken eggs | 13 |
neutralization tests | 13 |
received one | 13 |
malignant cells | 13 |
less likely | 13 |
positive predictive | 13 |
using anti | 13 |
antibody reacted | 13 |
phage displayed | 13 |
shelf life | 13 |
pulmonary disease | 13 |
antibiotic resistance | 13 |
lower levels | 13 |
acute phase | 13 |
term protection | 13 |
directed mutagenesis | 13 |
small intestine | 13 |
corticosteroid therapy | 13 |
clinical experience | 13 |
human immunology | 13 |
several days | 13 |
overall mortality | 13 |
highly purified | 13 |
viral fusion | 13 |
killed brv | 13 |
modified mrna | 13 |
cryptosporidium parvum | 13 |
messenger rna | 13 |
commercial kits | 13 |
cell membranes | 13 |
severe symptoms | 13 |
transfusion practices | 13 |
neonatal calf | 13 |
fusion efficiency | 13 |
terminal region | 13 |
testing methods | 13 |
mechanical ventilation | 13 |
weight loss | 13 |
several months | 13 |
signal intensities | 13 |
specific cytotoxic | 13 |
certain cases | 13 |
i antibodies | 13 |
vaccine virus | 13 |
medical research | 13 |
selected clones | 13 |
canine coronavirus | 13 |
igm response | 13 |
integral part | 13 |
routine testing | 13 |
expression systems | 13 |
checkpoint inhibitors | 13 |
specific immunity | 13 |
skeletal muscle | 13 |
recombinant dna | 13 |
viral membrane | 13 |
enzyme activity | 13 |
taken place | 13 |
cholera toxin | 13 |
previously unknown | 13 |
constant domain | 13 |
ige binding | 13 |
natural human | 13 |
pcr method | 13 |
cynomolgus macaques | 13 |
adoptive transfer | 13 |
elisa assay | 13 |
receptor interactions | 13 |
kg dose | 13 |
igg class | 13 |
laboratory tests | 13 |
adv particles | 13 |
heart block | 13 |
five different | 13 |
male patient | 13 |
epitope sequence | 13 |
tissue banking | 13 |
macular degeneration | 13 |
donor samples | 13 |
antigenic targets | 13 |
antiviral activity | 13 |
antiviral responses | 13 |
variable immunodeficiency | 13 |
small cell | 13 |
four times | 13 |
mm nacl | 13 |
cell patients | 13 |
pathogenic bacteria | 13 |
fluorescence intensity | 13 |
induce antibodies | 13 |
coagulation factor | 13 |
st century | 13 |
peritonitis virus | 13 |
poly dat | 13 |
blood inventory | 13 |
tumor growth | 13 |
studies performed | 13 |
sars virus | 13 |
ige antibodies | 13 |
cell antibody | 13 |
phosphate buffered | 13 |
clinical data | 13 |
fi lms | 13 |
clinical presentation | 13 |
sclerosing panencephalitis | 13 |
antibody formation | 13 |
bacterial species | 13 |
healthy control | 13 |
assay using | 13 |
activate complement | 13 |
protein engineering | 13 |
virus may | 13 |
per product | 13 |
old female | 13 |
lethal factor | 13 |
severe hemolytic | 13 |
effective way | 13 |
miu ml | 13 |
neutralization titers | 13 |
repeat donors | 13 |
mb plasma | 13 |
longer periods | 13 |
theraflex mb | 13 |
one must | 13 |
directed toward | 13 |
us food | 13 |
good manufacturing | 13 |
determining region | 13 |
vectored immunoprophylaxis | 13 |
days since | 13 |
plasma recipients | 13 |
irregular antibodies | 13 |
biomarker discovery | 13 |